Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD, AD/PD™ Session Spotlight

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/00/01/c0/0001c052-72e2-d909-cef9-7f0856455093/mza_1281226557431115393.jpg/600x600bb.jpg

The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

AD/PD™ on UNLOK

8 episodes

1 day ago

AD/PD™ is the leading international platform dedicated to exploring the latest breakthroughs and treatments in Alzheimer's, Parkinson’s, and related neurodegenerative diseases. The "AD/PD™ Session Spotlight" series is an AI-powered podcast that brings you key insights from the AD/PD™ Conference, with expert presentations and research discussions transformed into concise, easy-to-digest episodes. Join us as we uncover the latest innovations, explore groundbreaking research, and discuss the future of neurodegenerative disease treatments and therapies.

Life Sciences

Science

RSS

All content for The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases is the property of AD/PD™ on UNLOK and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/43489932/43489932-1744896200801-87633cc69c0a4.jpg

Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD, AD/PD™ Session Spotlight

The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

20 minutes 13 seconds

2 months ago

Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD, AD/PD™ Session Spotlight

In this episode, we dive into one of the most forward-looking conversations from the AD/PD™ 2025 International Conference — Forum Discussion 2, "Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD."

Moderated by Dr. Oskar Hansson (Sweden) and Dr. Melissa Murray (USA), this dynamic session was led by Dr. Rhoda Au (USA), Prof. Charlotte Teunissen (Netherlands), Dr. Danielle Graham (USA), Dr. Bryan Cobb (USA) and Dr. Tobias Bittner (Switzerland). The discussion explored how emerging biomarkers — from blood-based diagnostics to digital tools powered by AI — are reshaping how we detect and monitor Alzheimer’s disease. But how close are we to true clinical validation?

Key highlights include:

• The promise of IVD-cleared blood-based tests for amyloid positivity by 2025

• Global progress and regulatory differences in the US and Europe

• The critical role of clinical guidelines, education, and confirmatory testing

• How digital biomarkers may detect cognitive decline earlier than ever

• Four intended uses of digital tools in clinical and research settings

• Challenges in validating digital measures with the same rigor as biological ones

This episode is relevant for clinicians, researchers, biotech professionals, regulators, and digital health innovators working on early detection and precision medicine in Alzheimer’s disease.

This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.

The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.

https://adpd.kenes.com/